THIS IS A PHASE 1, OPEN-LABEL, AND MULTICENTER STUDY TO EVALUATE THE TOLERABILITY, SAFETY, PHARMACOKINETICS, AND EFFICACY OF TAK-385 IN JAPANESE PATIENTS WITH ANDROGEN DEPRIVATION TREATMENT-NAÏVE NONMETASTATIC PROSTATE CANCER.: